In Vivo Effect of Innate Immune Response Modulating Impurities on the Skin Milieu Using a Macaque Model: Impact on Product Immunogenicity

Journal of Pharmaceutical Sciences

Volumn 106, Issue 3, 2017, Pages 751-760

  Haile, Lydia A ^a   Puig, Montserrat ^a   Polumuri, Swamy K ^a   Ascher, Jill ^a   Verthelyi, Daniela ^a  

^a CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

Author keywords

biosimilar; biotechnology; immune response; immunology; injectables; skin

Indexed keywords

B7 ANTIGEN; BETA GLUCAN; CD40 ANTIGEN; CD69 ANTIGEN; CPG OLIGODEOXYNUCLEOTIDE; ENDOTOXIN; FLAGELLIN; INTERLEUKIN 6; INTERLEUKIN 8; MURAMYL DIPEPTIDE; POLYINOSINIC POLYCYTIDYLIC ACID; RASBURICASE; ANTIBODY; PATTERN RECOGNITION RECEPTOR; POLYCYTIDYLIC ACID;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; FEMALE; GENE EXPRESSION; IMMUNOGENICITY; IN VIVO STUDY; INNATE IMMUNITY; MACAQUE MODEL; MALE; NONHUMAN; RHESUS MONKEY; UPREGULATION; ANIMAL; ANIMAL MODEL; DRUG EFFECTS; HEK293 CELL LINE; HUMAN; IMMUNOGENETICS; IMMUNOLOGY; PHYSIOLOGY; SKIN; SUBCUTANEOUS DRUG ADMINISTRATION;

ANIMALS; ANTIBODIES; ENDOTOXINS; FEMALE; HEK293 CELLS; HUMANS; IMMUNITY, INNATE; IMMUNOGENETIC PHENOMENA; INJECTIONS, SUBCUTANEOUS; MACACA MULATTA; MALE; MODELS, ANIMAL; POLY C; RECEPTORS, PATTERN RECOGNITION; SKIN;

EID: 85007480213     PISSN: 00223549     EISSN: 15206017     Source Type: Journal    
DOI: 10.1016/j.xphs.2016.11.001     Document Type: Article

References (60)

1. 1 Rosenberg, A.S., Immunogenicity of biological therapeutics: a hierarchy of concerns. Dev Biol (Basel) 112 (2003), 15–21.
2. 2 Schellekens, H., Immunogenicity of therapeutic proteins: clinical implications and future prospects. Clin Ther 24:11 (2002), 1720–1740 [discussion: 1719].
3. 3 Kishnani, P.S., Goldenberg, P.C., DeArmey, S.L., et al. Cross-reactive immunologic material status affects treatment outcomes in Pompe disease infants. Mol Genet Metab 99:1 (2010), 26–33.
4. 4 Rosenberg, A.S., Verthelyi, D., Cherney, B.W., Managing uncertainty: a perspective on risk pertaining to product quality attributes as they bear on immunogenicity of therapeutic proteins. J Pharm Sci 101:10 (2012), 3560–3567.
5. 5 Schellekens, H., How to predict and prevent the immunogenicity of therapeutic proteins. Biotechnol Annu Rev 14 (2008), 191–202.
6. 6 Subramanyam, M., Immunogenicity of biotherapeutics—an overview. J Immunotoxicol 3:3 (2006), 151–156.
7. 7 Lee, S., Raw, A., Yu, L., et al. Scientific considerations in the review and approval of generic enoxaparin in the United States. Nat Biotechnol 31:3 (2013), 220–226.
8. 8 Rosenberg, A.S., Worobec, A., A risk-based approach to immunogenicity concerns of therapeutic protein products. Part 1: considering consequences of the immune response to a protein. Biopharm Int 17:11 (2004), 22–26.
9. 9 Wang, X., Hunter, A.K., Mozier, N.M., Host cell proteins in biologics development: identification, quantitation and risk assessment. Biotechnol Bioeng 103:3 (2009), 446–458.
10. 10 Medzhitov, R., Toll-like receptors and innate immunity. Nat Rev Immunol 1:2 (2001), 135–145.
11. 11 Kawai, T., Akira, S., The role of pattern-recognition receptors in innate immunity: update on Toll-like receptors. Nat Immunol 11:5 (2010), 373–384.
12. 12 Muralidharan, S., Mandrekar, P., Cellular stress response and innate immune signaling: integrating pathways in host defense and inflammation. J Leukoc Biol 94:6 (2013), 1167–1184.
13. 13 Gursel, M., Verthelyi, D., Klinman, D.M., CpG oligodeoxynucleotides induce human monocytes to mature into functional dendritic cells. Eur J Immunol 32:9 (2002), 2617–2622.
14. 14 Kwissa, M., Nakaya, H.I., Oluoch, H., Pulendran, B., Distinct TLR adjuvants differentially stimulate systemic and local innate immune responses in nonhuman primates. Blood 119:9 (2012), 2044–2055.
15. 15 Steinhagen, F., Kinjo, T., Bode, C., Klinman, D.M., TLR-based immune adjuvants. Vaccine 29:17 (2011), 3341–3355.
16. 16 Verthelyi, D., Kenney, R.T., Seder, R.A., Gam, A.A., Friedag, B., Klinman, D.M., CpG oligodeoxynucleotides as vaccine adjuvants in primates. J Immunol 168:4 (2002), 1659–1663.
17. 17 Fathallah, A.M., Bankert, R.B., Balu-Iyer, S.V., Immunogenicity of subcutaneously administered therapeutic proteins—a mechanistic perspective. AAPS J 15:4 (2013), 897–900.
18. 18 Hari, A., Flach, T.L., Shi, Y., Mydlarski, P.R., Toll-like receptors: role in dermatological disease. Mediators Inflamm, 2010, 2010, 437246.
19. 19 Miller, L.S., Toll-like receptors in skin. Adv Dermatol 24 (2008), 71–87.
20. 20 Nestle, F.O., Di Meglio, P., Qin, J.Z., Nickoloff, B.J., Skin immune sentinels in health and disease. Nat Rev Immunol 9:10 (2009), 679–691.
21. 21 Kollisch, G., Kalali, B.N., Voelcker, V., et al. Various members of the Toll-like receptor family contribute to the innate immune response of human epidermal keratinocytes. Immunology 114:4 (2005), 531–541.
22. 22 Lebre, M.C., van der Aar, A.M., van Baarsen, L., et al. Human keratinocytes express functional Toll-like receptor 3, 4, 5, and 9. J Invest Dermatol 127:2 (2007), 331–341.
23. 23 Mempel, M., Voelcker, V., Kollisch, G., et al. Toll-like receptor expression in human keratinocytes: nuclear factor kappaB controlled gene activation by Staphylococcus aureus is toll-like receptor 2 but not toll-like receptor 4 or platelet activating factor receptor dependent. J Invest Dermatol 121:6 (2003), 1389–1396.
24. 24 Terhorst, D., Kalali, B.N., Ollert, M., Ring, J., Mempel, M., The role of toll-like receptors in host defenses and their relevance to dermatologic diseases. Am J Clin Dermatol 11:1 (2010), 1–10.
25. 25 Udey, M.C., Skin dendritic cells in immunity and autoimmunity. J Investig Dermatol Symp Proc 9:1 (2004), 15–17.
26. 26 Napolitani, G., Rinaldi, A., Bertoni, F., Sallusto, F., Lanzavecchia, A., Selected Toll-like receptor agonist combinations synergistically trigger a T helper type 1-polarizing program in dendritic cells. Nat Immunol 6:8 (2005), 769–776.
27. 27 Verthelyi, D., Wang, V., Trace levels of innate immune response modulating impurities (IIRMIs) synergize to break tolerance to therapeutic proteins. PLoS One, 5(12), 2010, e15252.
28. 28 Zaitseva, M., Romantseva, T., Blinova, K., et al. Use of human MonoMac6 cells for development of in vitro assay predictive of adjuvant safety in vivo. Vaccine 30:32 (2012), 4859–4865.
29. 29 Sun, J., Li, N., Oh, K.S., et al. Comprehensive RNAi-based screening of human and mouse TLR pathways identifies species-specific preferences in signaling protein use. Sci Signal, 9(409), 2016, ra3.
30. 30 Geddes, K., Magalhaes, J.G., Girardin, S.E., Unleashing the therapeutic potential of NOD-like receptors. Nat Rev Drug Discov 8:6 (2009), 465–479.
31. 31 Hornung, V., Rothenfusser, S., Britsch, S., et al. Quantitative expression of toll-like receptor 1-10 mRNA in cellular subsets of human peripheral blood mononuclear cells and sensitivity to CpG oligodeoxynucleotides. J Immunol 168:9 (2002), 4531–4537.
32. 32 Takeda, K., Akira, S., Toll-like receptors. Curr Protoc Immunol, 109, 2015 14.12.1–14.12.10.
33. 33 Yin, Q., Fu, T.M., Li, J., Wu, H., Structural biology of innate immunity. Annu Rev Immunol 33 (2015), 393–416.
34. 34 Cervantes, J.L., Weinerman, B., Basole, C., Salazar, J.C., TLR8: the forgotten relative revindicated. Cell Mol Immunol 9:6 (2012), 434–438.
35. 35 Ketloy, C., Engering, A., Srichairatanakul, U., et al. Expression and function of Toll-like receptors on dendritic cells and other antigen presenting cells from non-human primates. Vet Immunol Immunopathol 125:1-2 (2008), 18–30.
36. 36 Klinman, D.M., Verthelyi, D., Takeshita, F., Ishii, K.J., Immune recognition of foreign DNA: a cure for bioterrorism?. Immunity 11:2 (1999), 123–129.
37. 37 Verthelyi, D., Ishii, K.J., Gursel, M., Takeshita, F., Klinman, D.M., Human peripheral blood cells differentially recognize and respond to two distinct CPG motifs. J Immunol 166:4 (2001), 2372–2377.
38. 38 Gujer, C., Sundling, C., Seder, R.A., Karlsson Hedestam, G.B., Lore, K., Human and rhesus plasmacytoid dendritic cell and B-cell responses to Toll-like receptor stimulation. Immunology 134:3 (2011), 257–269.
39. 39 Verthelyi, D., Adjuvant properties of CpG oligonucleotides in primates. Methods Mol Med 127 (2006), 139–158.
40. 40 Iwasaki, A., Medzhitov, R., Control of adaptive immunity by the innate immune system. Nat Immunol 16:4 (2015), 343–353.
41. 41 Grossberg, S.E., Oger, J., Grossberg, L.D., Gehchan, A., Klein, J.P., Frequency and magnitude of interferon β neutralizing antibodies in the evaluation of interferon β immunogenicity in patients with multiple sclerosis. J Interferon Cytokine Res 31:3 (2011), 337–344.
42. 42 Rodriguez, M., Campara, M., Haaf, C., Rasburicase in cancer-related hyperuricemia. Drugs Today (Barc) 47:8 (2011), 591–603.
43. 43 Barry, M., Cooper, C., Review of hepatitis B surface antigen-1018 ISS adjuvant-containing vaccine safety and efficacy. Expert Opin Biol Ther 7:11 (2007), 1731–1737.
44. 44 Garcon, N., Morel, S., Didierlaurent, A., Descamps, D., Wettendorff, M., Van Mechelen, M., Development of an AS04-adjuvanted HPV vaccine with the adjuvant system approach. BioDrugs 25:4 (2011), 217–226.
45. 45 Puig, M., Tosh, K.W., Schramm, L.M., et al. TLR9 and TLR7 agonists mediate distinct type I IFN responses in humans and nonhuman primates in vitro and in vivo. J Leukoc Biol 91:1 (2012), 147–158.
46. 46 Brubaker, S.W., Bonham, K.S., Zanoni, I., Kagan, J.C., Innate immune pattern recognition: a cell biological perspective. Annu Rev Immunol 33 (2015), 257–290.
47. 47 Allen, K.C., Champlain, A.H., Cotliar, J.A., et al. Risk of anaphylaxis with repeated courses of rasburicase: a Research on Adverse Drug Events and Reports (RADAR) project. Drug Saf 38:2 (2015), 183–187.
48. 48 Kasturi, S.P., Skountzou, I., Albrecht, R.A., et al. Programming the magnitude and persistence of antibody responses with innate immunity. Nature 470:7335 (2011), 543–547.
49. 49 Haile, L.A., Puig, M., Kelley-Baker, L., Verthelyi, D., Detection of innate immune response modulating impurities in therapeutic proteins. PLoS One, 10(4), 2015, e0125078.
50. 50 Barreiro, L.B., Marioni, J.C., Blekhman, R., Stephens, M., Gilad, Y., Functional comparison of innate immune signaling pathways in primates. PLoS Genet, 6(12), 2010, e1001249.
51. 51 Bhat, N., Fitzgerald, K.A., Recognition of cytosolic DNA by cGAS and other STING-dependent sensors. Eur J Immunol 44:3 (2014), 634–640.
52. 52 Iwasaki, A., Medzhitov, R., Regulation of adaptive immunity by the innate immune system. Science 327:5963 (2010), 291–295.
53. 53 Moura-Alves, P., Fae, K., Houthuys, E., et al. AhR sensing of bacterial pigments regulates antibacterial defence. Nature 512:7515 (2014), 387–392.
54. 54 Shi, J., Zhao, Y., Wang, Y., et al. Inflammatory caspases are innate immune receptors for intracellular LPS. Nature 514:7521 (2014), 187–192.
55. 55 Piccinini, A.M., Midwood, K.S., DAMPening inflammation by modulating TLR signalling. Mediators Inflamm, 2010, 2010, 672395.
56. 56 Akramiene, D., Kondrotas, A., Didziapetriene, J., Kevelaitis, E., Effects of beta-glucans on the immune system. Medicina (Kaunas) 43:8 (2007), 597–606.
57. 57 Hasiwa, N., Daneshian, M., Bruegger, P., et al. Evidence for the detection of non-endotoxin pyrogens by the whole blood monocyte activation test. ALTEX 30:2 (2013), 169–208.
58. 58 Buchacher, A., Krause, D., Wiry, G., Weinberger, J., Elevated endotoxin levels in human intravenous immunoglobulin concentrates caused by (1->3)-{beta}-D-glucans. PDA J Pharm Sci Technol 64:6 (2010), 536–544.
59. 59 Fennrich, S., Fischer, M., Hartung, T., et al. Detection of endotoxins and other pyrogens using human whole blood. Dev Biol Stand 101 (1999), 131–139.
60. 60 Wunderlich, C., Schumacher, S., Kietzmann, M., Pyrogen detection methods: comparison of bovine whole blood assay (bWBA) and monocyte activation test (MAT). BMC Pharmacol Toxicol, 15, 2014, 50.